Best Immunology Companies in Switzerland
The 31 best Immunology companies in Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Windward Bio.
- Immunology Market size is set to grow by USD 56.07 billion from 2022 t
Ranked: Best Immunology companies in Switzerland
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Windward Bio Company develops monoclonal antibody therapeutics for immunological and respiratory diseases | $365M | 6 mo ago | Series B | Luca Santarelli Founder | — | — | — | — |
| 2 | Alentis Therapeutics Developer of therapies for treating fibrosis, cirrhosis, and liver cancer | $184M | 24 mo ago | Series D | Thomas Baumert Founder & Board Member | 38 | WordPressMySQLPHP+19 | 35 patents Bispecific Claudin‑1/EGFR antibodies for oncology and liver fibrosis therapeutics | — |
| 3 | Anokion Developer of therapeutic proteins to treat autoimmune and allergic diseases | $112M | 48 mo ago | Deadpooled | — | 30 | WordPressMySQLPHP+13 | 65 patents Glyco‑engineered biologics targeting ASGR1 for inducing immune tolerance therapies. | — |
| 4 | ImmunOs Therapeutics Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $102M | 25 mo ago | Series C | Christoph Renner Co-Founder & CMO | 31 | — | 33 patents Engineered HLA fusion proteins for immune checkpoint modulation and enhanced antigen presentation | — |
| 5 | Granite Bio Developer of therapeutic antibodies that target inflammatory, autoimmune, and fibrotic conditions | $100M | 18 mo ago | Series B | Matthias Mack Founder | — | Cart FunctionalitySquarespace CommerceSquarespace+17 | — | — |
| 6 | Metrio Pharm Clinical stage Biopharma developing small molecule immune modulator against chronic immune disorders | $50M | 61 mo ago | Public | Thomas Christely CEO | 19 | PHPBootstrapNginx+4 | — | — |
| 7 | GlycoEra Developer of biologics for selective degradation of disease-driving extracellular proteins | $49M | 17 mo ago | Series B | — | 29 | WordPressMySQLPHP+15 | 24 patents Glycoengineered therapeutics for antibody targeting and glycan-directed protein degradation | — |
| 8 | Anergis Developer of vaccines against birch pollen allergy, ragweed and dust mites allergy | $49M | 127 mo ago | Deadpooled | — | 11 | — | 60 patents Peptide-based vaccines for treating birch pollen and house dust mite allergies | — |
| 9 | Polyneuron Developer of antibody catch technology for treatment antibody-mediated autoimmune diseases | $40M | 66 mo ago | Deadpooled | — | 9 | — | — | — |
| 10 | Mabylon Developer of therapeutics for allergies and neurodegenerative diseases | $39M | 15 mo ago | Series B | Alcide Barberis CEO | — | PHPGoogle MapsBootstrap+13 | 38 patents Therapeutic antibodies targeting allergens and ASC inflammasome proteins for allergy and inflammation treatment | — |
| 11 | Aurealis Therapeutics Developer of cell and gene therapies for chronic wounds and cancer | $22M | 23 mo ago | Series B | — | 17 | WordPressMySQLPHP+21 | 10 patents Chloride-responsive gene expression platforms for microbial biotechnology | — |
| 12 | AB2 Bio Research-based company developing drugs for the treatment of inflammatory diseases | $21M | 130 mo ago | Series B | — | 10 | Apache HTTP ServerGoogle Font APIModernizr+5 | 71 patents Therapeutic IL-18 binding proteins and antibodies for treating inflammatory diseases | — |
| 13 | TECregen Developer of ligand-based solutions to restore and preserve thymus function | $13M | 10 mo ago | Seed | Ignacio Moraga Co-Founder & Chief Scientific Officer | — | — | — | — |
| 14 | Somagenetix Developer of gene therapies to treat inherited immune diseases | $12M | 25 mo ago | Series A | Janine Reichenbach Co-Founder | 3 | — | — | — |
| 15 | Allegria Therapeutics Developer of therapeutics for allergy and inflammatory diseases | $4M | 11 mo ago | Seed | Maria Van Dongen Chief Executive Officer & Co-founder | — | — | — | — |
| 16 | Mysthera Therapeutics Developer of therapuetics for auto-immune diseases | $4M | 38 mo ago | Seed | Marta Marti Co-Founder | — | — | — | — |
| 17 | REMUUN Developer of therapeutic monoclonal antibodies | $170K | 19 mo ago | Seed | Richard Chahwan Founder & CEO | — | — | — | — |
| 18 | NXI Therapeutics Developer of immunotherapies for autoimmune diseases and organ transplantation | $159K | 52 mo ago | Funding Raised | Rajesh Jayachandran Co-Founder | 4 | — | — | — |
| 19 | Endotelix Developer of solutions for treating antiphospholipid syndrome | $107K | 44 mo ago | Seed | Karim Brandt Co-Founder & CEO | — | — | — | — |
Top 12 Immunology companies in Switzerland
#1
Series B · Basel, Basel Stadt · founded 2020$365Mraised▾
Company develops monoclonal antibody therapeutics for immunological and respiratory diseases. It focuses on advancing a thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development. It also creates novel, long-acting bispecific programs for immunological diseases. The company's lead candidate, WIN378, is a fully human monoclonal antibody engineered for extended half-life and effector silencing, targeting the TSLP ligand to treat asthma, COPD, and other inflammatory phenotypes.
- May 2026Series B$165M
- Jan 2025Series A$200M
#2
Series B · Schlieren, Zurich · founded 2015$38.7Mraised▾
Developer of therapeutics for allergies and neurodegenerative diseases. It offers antibody therapies for Peanut allergy, pollen allergy, ALS, neuroinflammation, and Alzheimer's disease.
- Aug 2025Series B$37M
- Sep 2024Grant (prize money)$1.5M
- May 2020Grant (prize money)$55.5K
- Dec 2019Grant (prize money)$55.1K
#3
Seed · Basel, Basel Stadt · founded 2023$12.6Mraised▾
Developer of ligand-based solutions to restore and preserve thymus function. The company engineers solutions to regenerate the thymus’s natural ability to create and maintain a functional immune system. It focuses on enhancing immune resilience and improving infection resistance. The company also accelerates recovery for patients with thymus-related disorders.
- Jan 2026Seed$12.6M
#4
Series B · Basel, Basel Stadt · founded 2021$100Mraised▾
Developer of therapeutic antibodies that target inflammatory, autoimmune, and fibrotic conditions. The pipeline consist of GRT-001 for depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP and GRT-002 has proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.
- Apr 2025Series A$30M
- Apr 2025Series B$70M
#5
Series D · Basel, Basel Stadt · founded 2019 · 38 employees$184.3Mraised▾
Developer of therapies for treating fibrosis, cirrhosis, and liver cancer. They have developed a gene expression platform. Their drug candidates (monoclonal antibodies) target a cell surface protein, which is being investigated for liver disease and cancer. The products include ALE-F02, CLDN1 for Liver Fibrosis (F3/F4) and kidney fibrosis, and ALE-C04, CLDN1 for Hepatocellular Carcinoma (HCC), and Cholangiocarcinoma.
- Nov 2024Series D$181.4M
- Apr 2023Series C$105M
- Jun 2021Series B$67M
- Apr 2019Series A$12.3M
#6
Series B · Schlieren, Zurich · founded 2020 · 29 employees$49Mraised▾
Developer of biologics for selective degradation of disease-driving extracellular proteins. It focuses on precision therapeutics for autoimmune diseases by targeting circulating proteins, specifically autoantibodies. The company's platform enables rapid, selective, and deep degradation of target proteins without broad immunosuppression. This approach offers an improved safety profile and the potential for earlier disease intervention, which could improve patient quality of life and lower healthcare costs. The platform can target and degrade any circulating extracellular protein of interest, applicable to diseases driven by circulating proteins, such as autoimmune and neurological diseases.
- May 2025Series B$130M
- Jan 2024Series A—
- Nov 2021Series A$49M
#7
Seed · Basel, Basel Stadt · founded 2023$3.5Mraised▾
Developer of therapeutics for allergy and inflammatory diseases. The company is working on RNA processing and the discovery of peptide-based therapeutics for cell-mediated diseases such as allergy and inflammatory conditions.
- Dec 2025Seed$5.1M
- May 2024Seed$3.5M
#8
Series B · Basel, Basel Stadt · founded 2010 · 17 employees$22Mraised▾
Developer of cell and gene therapies for chronic wounds and cancer. The company focuses on creating therapies for unmet medical needs. Its multi-target cell and gene therapy platform addresses complex multi-factorial diseases. The company generates pre-clinical, clinical, and health-economic evidence.
- Nov 2024Series B$9M
- 2021Series A—
- Aug 2017Series A$5.8M
- Jan 2016Seed$3.3M
#9
Series C · Schlieren, Zurich · founded 2013 · 31 employees$102.5Mraised▾
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company has an HLA-based pipeline that includes first-in-class immunotherapies for the treatment of cancer and autoimmune diseases. The Company´s lead product candidate, IOS-1002, is an HLA-based protein that blocks the activation of three different immunosuppressive receptors (also known as checkpoints) on innate and adaptive immune cells
- Sep 2024Series C$11M
- Jun 2022Series B$74M
- Dec 2019Series A$15.2M
- Oct 2018Series A—
#10
Series A · Zurich, Zurich · founded 2018 · 3 employees$11.7Mraised▾
Developer of gene therapies to treat inherited immune diseases. Through genetically modified phagocytes, the company uses proprietary technologies to deliver ex-vivo gene treatments to patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastasis.
- Oct 2024Series A$11.7M
#11
Deadpooled · Ecublens, Fribourg · founded 2010 · 30 employees$112.5Mraised▾
Developer of therapeutic proteins to treat autoimmune and allergic diseases. It offers antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. It offers platform technology for antigen-specific tolerance that can be translated to virtually any protein in numerous clinical indications.
- Oct 2022Series B$35M
- Sep 2019Series B$40M
- May 2014Series A$37.5M
#12
Public · Richterswil, Zurich · founded 2007 · 19 employees$49.8Mraised▾
MetrioPharm is a clinical stage pharmaceutical biotech company developing new medications against chronic immune disorders. Their focus is on Immune-Mediated Inflammatory Diseases (IMIDs) such as psoriasis, arthritis and multiple sclerosis. The primary target of drug molecules from MetrioPharm's MP1000 platform is the macrophage. Molecules of MetrioPharm's MP1000 drug platform including our lead drug MP1032 have the ability to modulate the activation state of macrophages from their inflammatory and destructive M1 state towards the M2 state. Their drug candidates have shown the potential to be significantly safer and more tolerable than existing therapies. MetrioPharm's lead compound MP1032 is currently in phase II clinical testing to treat Psoriasis
- Oct 2021Series E$29.7M
- Aug 2021Grant (prize money)$8.9M
- Dec 2018Series D$20.1M
- Mar 2015Grant (prize money)—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in Switzerland
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 856 Switzerland-affiliated papers.
- Karger Publishers183
- Ludwig Cancer Research75
- Roche58
- University of Zurich57
- University Hospital of Zurich57
- Immune system4→84
- Tumor microenvironment1→27
- Cancer immunotherapy3→26
- Immune checkpoint1→17
- Cytotoxic T cell4→19
- Immune system11→104
- Cancer4→43
- Oncology5→40
- Tumor microenvironment3→37
- Internal medicine6→34
- Immune system6→34
- Cancer4→31
- Disease2→18
- Clinical trial1→16
- Melanoma3→12
Where immunology is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.